Internal medicine connects with themes related to Dosing in his study. He combines topics linked to Internal medicine with his work on Dosing. John P.H. Wilding applies his multidisciplinary studies on Pathology and Gastroenterology in his research. Gastroenterology and Pathology are two areas of study in which John P.H. Wilding engages in interdisciplinary work. Many of his studies involve connections with topics such as Tolerability and Alternative medicine. His work on Tolerability is being expanded to include thematically relevant topics such as Adverse effect. He performs integrative study on Adverse effect and Alternative medicine in his works. His study ties his expertise on Ingestion together with the subject of Endocrinology. John P.H. Wilding combines topics linked to Endocrinology with his work on Ingestion.
John P.H. Wilding conducted interdisciplinary study in his works that combined Internal medicine and Surgery. John P.H. Wilding merges Surgery with Internal medicine in his study. John P.H. Wilding regularly links together related areas like Insulin in his Endocrinology studies. John P.H. Wilding connects Insulin with Insulin resistance in his research. His Insulin resistance study frequently links to adjacent areas such as Glucose homeostasis. His study deals with a combination of Obesity and Leptin. While working on this project, he studies both Leptin and Obesity. Diabetes mellitus and Blood pressure are two areas of study in which John P.H. Wilding engages in interdisciplinary research. He undertakes multidisciplinary studies into Blood pressure and Diabetes mellitus in his work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A role for glucagon-like peptide-1 in the central regulation of feeding
M. D. Turton;D. O'Shea;I. Gunn;S. A. Beak.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker;Stephen D Wiviott;Itamar Raz;Kyungah Im.
The Lancet (2019)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer;Arne Astrup;Ken Fujioka;Frank Greenway.
The New England Journal of Medicine (2015)
Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome
Steven R Coughlin;Lynn Mawdsley;Julie A Mugarza;Peter M A Calverley.
European Heart Journal (2004)
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
Jan Bolinder;Östen Ljunggren;Joel Kullberg;Lars Johansson;Lars Johansson.
The Journal of Clinical Endocrinology and Metabolism (2012)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod;Matthew A. Cavender;Alex Z. Fu;John P. Wilding.
Food fails to suppress ghrelin levels in obese humans.
P. J. English;M. A. Ghatei;I. A. Malik;S. R. Bloom.
The Journal of Clinical Endocrinology and Metabolism (2002)
Management of obesity
George A Bray;Gema Frühbeck;Donna H Ryan;John P H Wilding.
The Lancet (2016)
Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.
G.A. Bray;K.K. Kim;J.P.H. Wilding.
Obesity Reviews (2017)
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
Jay S. Skyler;George L. Bakris;Ezio Bonifacio;Tamara Darsow.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: